Elizabeth Miller
Psychiatric/Mental Health · Austintown, OHNPI 1720620198
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 33.6% of the total. Reporting peaked in 2022 at $112 and has fallen 68.7% since, to $35 in 2025. That places this record below the midpoint for psychiatric/mental health clinicians in OH, where the typical reported total is $613.
Across 18 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$111
- Vanda Pharmaceuticals Inc.$71
- Alkermes, Inc.$60
- AbbVie$22
- Sunovion Pharmaceuticals Inc.$18
- Lundbeck LLC$17
- plus $30 from 2 others
What the payments were for
- Food & beverage$330100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $111 |
| Vanda Pharmaceuticals Inc. | 3 | $71 |
| Alkermes, Inc. | 3 | $60 |
| AbbVie | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
How this compares
$330 in reported general payments places this provider in the 35th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Paliperidone ErPaliperidone | 12 | $492 |
| Donepezil Hcl | 34 | $195 |
| Aripiprazole | 11 | $194 |
| Divalproex Sodium | 25 | $170 |
| Hydroxyzine Pamoate | 19 | $119 |
| Lisinopril | 21 | $67 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Austintown
- Kyle GuterbaAustintown$70K
- Diana IsaacsAustintown$52K
- Stephanie SteckerAustintown$10K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.